ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Lowered by StockNews.com

ProQR Therapeutics (NASDAQ:PRQR) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

A number of other analysts also recently weighed in on the stock. Citigroup boosted their target price on shares of ProQR Therapeutics from $1.80 to $2.00 and gave the stock a “buy” rating in a report on Thursday, April 18th. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of ProQR Therapeutics in a research report on Friday, May 10th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $2.50 price objective on shares of ProQR Therapeutics in a research note on Friday, May 10th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $3.38.

ProQR Therapeutics Stock Performance

PRQR stock opened at $1.71 on Friday. The company’s fifty day moving average price is $1.91 and its 200-day moving average price is $2.05. ProQR Therapeutics has a one year low of $1.11 and a one year high of $3.29. The company has a market capitalization of $139.12 million, a PE ratio of -4.62 and a beta of 0.35.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.02. The business had revenue of $4.83 million for the quarter, compared to analysts’ expectations of $3.31 million. ProQR Therapeutics had a negative net margin of 260.75% and a negative return on equity of 61.58%. On average, research analysts predict that ProQR Therapeutics will post -0.37 EPS for the current fiscal year.

Institutional Investors Weigh In On ProQR Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. EP Wealth Advisors LLC bought a new position in ProQR Therapeutics in the first quarter worth approximately $26,000. Acadian Asset Management LLC bought a new position in shares of ProQR Therapeutics during the 1st quarter worth $56,000. RFG Advisory LLC purchased a new position in shares of ProQR Therapeutics during the first quarter valued at $73,000. BNP Paribas Financial Markets raised its holdings in shares of ProQR Therapeutics by 120.1% in the first quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock valued at $80,000 after acquiring an additional 19,100 shares in the last quarter. Finally, Ikarian Capital LLC raised its holdings in shares of ProQR Therapeutics by 2.3% in the first quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock valued at $1,098,000 after acquiring an additional 10,958 shares in the last quarter. 32.65% of the stock is owned by institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).